Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kalvista Pharmaceuticals Inc
(NQ:
KALV
)
10.66
+0.20 (+1.96%)
Streaming Delayed Price
Updated: 11:54 AM EDT, Sep 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
153,873
Open
10.59
Bid (Size)
10.65 (2)
Ask (Size)
10.67 (2)
Prev. Close
10.46
Today's Range
10.40 - 10.77
52wk Range
7.210 - 16.88
Shares Outstanding
34,233,643
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
September 10, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Appoints Brian Piekos as Chief Financial Officer
September 10, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Performance
YTD
-12.22%
-12.22%
1 Month
-17.84%
-17.84%
3 Month
-13.01%
-13.01%
6 Month
-14.20%
-14.20%
1 Year
+5.70%
+5.70%
More News
Read More
KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024
September 06, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update
September 05, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema
September 03, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium
August 29, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema
August 15, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday
July 12, 2024
Via
Benzinga
KALV Stock Earnings: KalVista Pharma Misses EPS for Q4 2024
July 11, 2024
Via
InvestorPlace
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
July 11, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11
June 27, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema
June 18, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024
June 06, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024
June 03, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema
May 31, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024
May 24, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
May 21, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
May 01, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
April 22, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
